Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Wilson Disease
- Main trialPhase 1/2
- “The primary objectives of this study are to evaluate the safety of single IV doses of UX701 in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate the effect of UX701 on copper regulation.”In the company’s words, NCT04884815 on ClinicalTrials.gov
- Other names
- rivunatpagene miziparvovec
Other drugs for Wilson Disease
Coming up1
- Mar 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Mar 2029 | A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026